Celltrion headquarters in Yeonsu-gu, Incheon (Celltrion)
South Korean biopharmaceutical firm Celltrion stated Friday it achieved report income within the third quarter, pushed largely by elevated world prescriptions of its flagship biosimilar merchandise.
In line with a regulatory submitting, Celltrion posted consolidated gross sales of 881.9 billion received ($645.7 million) for the quarter, a 31.2 p.c enhance from the identical interval final 12 months. Working revenue totaled 207.7 billion received, with an working margin of 23.6 p.c. Specifically, cumulative gross sales for the primary three quarters reached 2.49 trillion received, surpassing the corporate’s annual income from the earlier 12 months.
The corporate attributed this achievement to sturdy world demand for its biosimilars, particularly in Europe and Latin America. Key merchandise — Remsima SC, Yuflyma and Vegzelma — generated a mixed 342.5 billion received in income, marking a year-on-year progress of 112.5 p.c.
Celltrion acknowledged it expects to fulfill its annual income goal of three.5 trillion received, with sturdy biosimilar gross sales in Europe and Latin America anticipated to additional drive progress.
“The record-breaking gross sales had been supported by each elevated biosimilar prescriptions and improved price efficiencies,” a Celltrion official stated. “We’re dedicated to sustaining progress and maximizing our market attain.”
